Maintenance darunavir/ritonavir monotherapy to prevent perinatal HIV transmission, ANRS-MIE 168 MONOGEST study

Abstract Objectives Because NRTIs can have fetal toxicities, we evaluated a perinatal NRTI-sparing strategy to prevent perinatal HIV transmission. Our primary objective was to determine the proportion maintaining a viral load (VL) of

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of antimicrobial chemotherapy 2023-07, Vol.78 (7), p.1711-1722
Hauptverfasser:	Mandelbrot, Laurent, Tubiana, Roland, Frange, Pierre, Peytavin, Gilles, Le Chenadec, Jerome, Canestri, Ana, Morlat, Philippe, Brunet-Cartier, Cécile, Sibiude, Jeanne, Peretti, Delphine, Chambrin, Véronique, Chabrol, Amélie, Bui, Eida, Simon-Toulza, Caroline, Marchand, Lucie, Paul, Christelle, Delmas, Sandrine, Avettand-Fenoel, Véronique, Warszawski, Josiane
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-HIV Agents Darunavir Female Gynecology and obstetrics HIV Infections - drug therapy HIV Infections - prevention & control Human health and pathology Humans Infant, Newborn Infectious diseases Life Sciences Norethindrone - therapeutic use Original Research Pharmaceutical sciences Pharmacology Pregnancy Ritonavir Santé publique et épidémiologie Treatment Outcome Viral Load
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract Objectives Because NRTIs can have fetal toxicities, we evaluated a perinatal NRTI-sparing strategy to prevent perinatal HIV transmission. Our primary objective was to determine the proportion maintaining a viral load (VL) of
ISSN:	0305-7453 1460-2091
DOI:	10.1093/jac/dkad161